![]() |
Market Research Report
Adrenoleukodystrophy (ALD) - Market Insights, Epidemiology and Market Forecast-2030 |
||||||
Published by | DelveInsight Business Research LLP | Product code | 973319 | ||||
Published | Pre-Order | Content info | 200 Pages Delivery time: 10 business days |
||||
Price |
|
Adrenoleukodystrophy (ALD) - Market Insights, Epidemiology and Market Forecast-2030 | ||
Published: Pre-Order | Content info: 200 Pages |
|
DelveInsight's 'Adrenoleukodystrophy (ALD) - Market Insights, Epidemiology and Market Forecast-2030' report delivers an in-depth understanding of the Adrenoleukodystrophy, historical and forecasted epidemiology as well as the Adrenoleukodystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Adrenoleukodystrophy (ALD) market report provides current treatment practices, emerging drugs, and Adrenoleukodystrophy market share of the individual therapies, current and forecasted Adrenoleukodystrophy market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Adrenoleukodystrophy treatment practice, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2017-2030
Adrenoleukodystrophy (ALD) is an X-linked recessive genetic disorder caused by the abnormality in the ABCD1 gene present on the X chromosome that leads to the accumulation of very-long-chain fatty acids (VLCFAs) in the brain, nervous system, and adrenal gland. The accumulation of VLCFAs leads to the deterioration of the myelin sheath, and without the sheath, neurons cannot conduct action potentials, this leads to the development of seizures and hyperactivity. Currently, no drug is approved for the treatment of Adrenoleukodystrophy and the available treatment options include hormone replacement therapy, dietary therapy with Lorenzo's oil and Hematopoietic stem cell transplantation, using either umbilical cord or bone marrow stem cells.
The diagnosis of Adrenoleukodystrophy is difficult as its symptoms are similar to other diseases such as attention deficit hyperactivity disorder, epilepsy, autism, and other learning disabilities. The diagnosis is done by the use of diagnostic assays, imaging tests, adrenal function testing, and prenatal diagnosis. In recent years various countries started the newborn screening programs to identify the conditions that may affect a baby's long-term health and survival. The newborn screening programs also included the screening of Adrenoleukodystrophy and gained huge success in early detection and cost-saving.
The DelveInsight Adrenoleukodystrophy market report gives a thorough understanding of Adrenoleukodystrophy by including details such as disease definition, clinical aspects, symptoms, causes, inheritance pattern, pathophysiology, and diagnosis. It covers the details of conventional and current medical therapies available in the Adrenoleukodystrophy market for the treatment of the condition. It also provides treatment guidelines for Adrenoleukodystrophy in the US and Europe.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Adrenoleukodystrophy in the 7MM, Gender-specific Prevalence of Adrenoleukodystrophy in the 7MM, Gender-specific Diagnosed Prevalence of Adrenoleukodystrophy in the 7MM, and Type-specific Diagnosed Prevalence of ALD in Males in the 7MM. The epidemiology section covers the 7MM countries, the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from the year 2017 to 2030.
As per DelveInsight's analysis, in 2017, the total prevalent population of Adrenoleukodystrophy in the 7MM was 55,242. Based on the type of ALD, it was also assessed that majority of the patients suffer from Cerebral ALD (CALD), with 1,160 cases observed in the US, in 2017, while Adrenomyeloneuropathy (AMN) and Addison Disease account for nearly 774, and 314 cases of the total diagnosed male symptomatic ALD population. Out of the total diagnosed male cases, CALD includes 1,160 cases, which is further divided based on age, i.e., Childhood CALD (894 cases), Adolescent CALD (169 cases), and Adult CALD (97 cases) in 2017 in the US.
Among the European five countries, Germany had the highest diagnosed prevalent population of ALD with 1,895 cases, followed by France and the United Kingdom. On the other hand, Italy had the lowest diagnosed prevalent population of 1,126 in 2017.
The epidemiology segment also provides the Adrenoleukodystrophy epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The drug chapter segment of the Adrenoleukodystrophy report encloses the detailed analysis of Adrenoleukodystrophy late stage (Phase III and Phase II) pipeline drugs. It also helps to understand the Adrenoleukodystrophy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of drugs, and the latest news and press releases around them.
Lenti D is an investigational gene therapy that is in Phase II/III stage of development for the treatment of cerebral ALD (CALD). Currently, bluebird bio is enrolling patients for a Phase III study (ALD-104) designed to assess the efficacy and safety of Lenti-D after myeloablative conditioning using busulfan and fludarabine in patients with CALD. Additionally, the company is conducting a long-term safety and efficacy follow-up study (LTF-304) for patients who have participated in ALD-102 and were treated with Lenti-D.
Leriglitazone (MIN-102) is a metabolite of pioglitazone which shows an excellent brain penetration and safety profile, allowing PPAR gamma engagement in the CNS above the level that can be safely achieved with pioglitazone and other glitazones. The drug candidate is in Phase II/III stage of development for the treatment of both cerebral ALD and Adrenomyeloneuropathy (AMN).
The Adrenoleukodystrophy market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Adrenoleukodystrophy market trends by analyzing the impact of current and emerging therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a thorough detail of Adrenoleukodystrophy market trend of each current available and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Adrenoleukodystrophy market in 7MM is expected to change in the study period 2017-2030.
This section includes a glimpse of the Adrenoleukodystrophy market in the 7MM.
This section provides the total Adrenoleukodystrophy market size and market size by therapies in the United States.
The market size for ALD was USD 993 million in 2017 in the Seven Major Markets. DelveInsight's analysts estimate that the market is expected to experience a significant rise in the coming years. Although, a noticeable growth can be seen in the upcoming year, owing to the launch of Lenti-D (Gene therapy; Bluebird Bio), and Leriglitazone (MIN-102) (Minoryx Therapeutics).
The total Adrenoleukodystrophy market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total market size of Adrenoleukodystrophy in Japan was USD 111.57 million in 2017.
This section focusses on the rate of uptake of the therapies in the market and potential drugs expected to get launched in the market during the study period 2017-2030. The analysis covers Adrenoleukodystrophy market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Adrenoleukodystrophy key players involved in developing targeted therapeutics.
The report covers the detailed information of collaborations, acquisition, merger, licensing, and patent details for Adrenoleukodystrophy emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
To keep up with current market trends, we take KOLs and SME's opinion working in the Adrenoleukodystrophy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or the Adrenoleukodystrophy market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform Competitive and Market Intelligence analysis of the Adrenoleukodystrophy Market by using various Competitive Intelligence tools that includes - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Key Market Forecast Assumptions for Elivaldogene autotemcel (Lenti D)
Key Market Forecast Assumptions for Leriglitazone (MIN-102)
Key Market Forecast Assumptions for MGTA-456